FDA warns GSK on manufacturing practices at Canada plant

June 24, 2014 3:08 PM

4 0

WASHINGTON, June 24 (Reuters) - The U.S. Food and Drug Administration has warned GlaxoSmithKline Plc that one of its plants in Canada violated quality control standards during the manufacture of its influenza vaccine Flulaval.

In a warning letter dated June 12, the FDA said the company had failed to take appropriate steps to prevent microbiological contamination of drugs, among other violations.

Read more

To category page

Loading...